Moderna sues Pfizer/BioNTech over COVID-19 vaccine patent infringement
![](/46/pdcnewsitem/11/85/96/2.png)
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020.
Moderna has sued Pfizer and German partner BioNTech for patent infringement regarding the development of the first COVID-19 vaccine approved in the United States, with allegations of copied technology developed by Moderna before the pandemic.
The lawsuit, filed in the US District Court in Massachusetts, will also be filed in the Regional Court of Dusseldorf, Germany. Moderna Chief Executive Stephane Bancel confirmed: “We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic.”
As two of the first groups to develop vaccines for the novel SARS-CoV-2 virus, Moderna and Pfizer/BioNTech witnessed a revenue windfall as the regulatory bodies such as the US FDA granted emergency use authorization for each vaccine. Moderna’s COVID-19 vaccine was granted emergency use authorization a week after the Pfizer/BioNTech vaccine, with the former bringing Moderna USD $10.4 billion in revenue and the latter raking in USD $22 billion for Pfizer.
A Pfizer spokesperson stated in an email statement: “We are surprised by the litigation given the COVID-19 vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer…. We will vigorously defend against all allegations of patent infringement.”
The vaccines produced by both Moderna and Pfizer/BioNTech involve mRNA technology that teaches human cells how to make a protein that will trigger an immune response. Moderna alleges that Pfizer/BioNTech leveraged mRNA technology patented by Moderna between 2010–2016, well before the outbreak of SARS-CoV-2 in 2019, for the development of their mRNA vaccine. Two types of intellectual property rights are alleged to have been infringed. One involves the mRNA structure, which Moderna claims to have begun developing in 2010. The second involves the coding of a full-length spike protein that was allegedly created while developing a vaccine for the coronavirus responsible for MERS. While Moderna has stated that the lawsuit is not meant to prevent access to COVID-19 vaccines, the pharmaceutical company, just over a decade old, claims that it does expect pharma giants such as Pfizer and BioNTech to respect their intellectual property rights.
Legal experts and analysts expect the dispute to take years. Shares for each company were down by the Friday afternoon trade.
Source: Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine | Reuters
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance